Each full guideline is presented below, in alphabetical order, with a short non-technical summary alongside the main guideline. The non-technical summary is less detailed than the full guideline and if you are reading this because it is relevant to your own healthcare, please do discuss any concerns or questions with your healthcare professionals.

* Guidelines currently being revised

Antiretroviral treatment

• Antiretroviral treatment for adults living with HIV-1 2022 (2023 interim update)

• View non-technical summary of the BHIVA treatment guidelines

• View non-technical summary about injectable HIV treatment

• Webcast of Dr Laura Waters summarising ART guidelines

• E-learning module

Hepatitis

• The 2014 viral hepatitis guidelines have been archived and new hepatitis guidelines are being written.
  In the meantime, please refer to https://www.eacsociety.org/guidelines/eacs-guidelines/

• A non-technical summary will accompany the updated guidelines

HIV-2

• Management of HIV-2 2021

• View non-technical summary

• E-learning module

Immunisation

• Immunisation for adults with HIV: SARS-CoV-2 (COVID-19) 2021 - view consultation version

• View non-technical summary

• Use of vaccines in HIV-positive adults 2015 *

• A non-technical summary will accompany the updated guidelines

• E-learning module

Malignancies

The BHIVA guidelines for HIV-associated malignancies 2014 have been archived. Instead, more recent, evidence-based, pan-European guidelines are available.

Corticosteroids, cancer chemotherapy and biologics: opportunistic infection prophylaxis
See European AIDS Clinical Society (EACS) guidelines:
https://www.eacsociety.org/guidelines/eacs-guidelines/

Kaposi’s sarcoma
See European Society of Medical Oncology (ESMO) guidelines:
https://www.bhiva.org/file/62c6fb02d1597/PIIS0959804919301364.pdf

(NB These are links to external guidelines for which BHIVA has no responsibility)

Monitoring

• Routine investigation and monitoring of adult HIV-1-positive individuals 2016 (2019 interim update)

  Please note: We delayed the full review of the monitoring guidelines pending data from 12-monthly viral load monitoring from observational studies in the first year of the COVID-19 pandemic. These guidelines are now undergoing full review.

• A non-technical summary will accompany the updated guidelines

• E-learning module

Opportunistic infection (OI)

The 2011 OI guidelines (Treatment of opportunistic infection in HIV-seropositive individuals 2011) are being updated and published chapter-by-chapter, using GRADE methodology. Each chapter will be available here when complete and will replace the corresponding chapter from the 2011 guidelines. A non-technical summary will accompany each chapter and a section on supporting patients to apply to the whole guideline is in preparation. UK-CAB (community) members are involved in the writing and/or proofreading of each chapter, and where not listed as authors are the UK-CAB members of the Guidelines Subcommittee.

• BHIVA guidelines on the management of opportunistic infection in people living with HIV:
  The clinical investigation and management of pyrexia of unknown origin 2023

• View non-technical summary

• BHIVA guidelines on the management of opportunistic infection in people living with HIV:
  The clinical management of non-tuberculous mycobacteria 2023 (consultation version)

• BHIVA guidelines on the management of opportunistic infection in people living with HIV:
  The clinical management of gastrointestinal opportunistic infections 2020 (2022 interim update)

• View non-technical summary

• BHIVA guidelines on the management of opportunistic infection in people living with HIV:
  The clinical management of candidiasis 2019 (2022 interim update)

• View non-technical summary

• Treatment of opportunistic infection in HIV-seropositive individuals 2011 *

Post-exposure prophylaxis (PEP)

• UK Guideline for the use of HIV Post-Exposure Prophylaxis 2021

• These guidelines do not have a BHIVA non-technical summary, as many resources are already available

Pre-exposure prophylaxis (PrEP)

• BHIVA/BASHH guidelines on the use of HIV pre-exposure prophylaxis (PrEP) 2018 *

• These guidelines do not have a BHIVA non-technical summary, as many resources are already available

• E-learning module

Pregnancy

• Management of HIV in pregnancy and postpartum 2018 (2020 third interim update)

• View non-technical summary (reviewed with 2020 third interim update)

• E-learning module

Testing

• BHIVA/BASHH/BIA adult HIV testing guidelines 2020

• View non-technical summary

• BHIVA, BIA and BASHH rapid guidance on assumed consent for opt-out blood-borne virus testing in Emergency Departments (consultation version)

• E-learning module

Tuberculosis (TB)

• Management of tuberculosis in adults living with HIV 2018 (2023 interim update)

• View non-technical summary (reviewed with 2023 interim update)

• E-learning module

Guidelines produced by other organisations

• BVHG / BASL / BSG / BHIVA / BIA / CVN guidelines for management of chronic HCV infection 2017 (2)

• BVHG / BASL / BSG / BHIVA / BIA / CVN guidelines for management of chronic HCV infection 2017 (1)

• HIV testing: encouraging uptake - NICE quality standard [QS157] 2017

• Kidney and pancreas transplantation in patients with HIV 2015

EAGA guidance on HIV post-exposure prophylaxis (PEP)

• Updated guidance on occupational HIV post-exposure prophylaxis (PEP) from the UK Chief Medical Officers' Expert Advisory Group on AIDS (EAGA)